CVRx reiterated plans to discuss the preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics conference on Tuesday, March 21, 2023 at 10:58 am Eastern Time in Boston. These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina/ Additionally, CVRx will sponsor a symposium, "Baroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study", at the THT 2023 conference starting at 12:30 pm ET. Dr. Zile’s slides and the slides presented at the symposium will be filed on a Form 8-K concurrent with Dr. Zile’s presentation.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVRX:
- CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call
- Lake Street buyers of CVRx after BeAT-HF trial data
- CVRx Nosedives after Heart Treatment Trial Fails
- CVRx reports preliminary results of BeAT-HF post-market clinical trial
- CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial